期刊文献+

伊马替尼治疗慢性髓细胞性白血病不良反应的临床护理措施 被引量:5

下载PDF
导出
摘要 目的探讨伊马替尼治疗慢性髓细胞性白血病不良反应的临床护理方法。方法选取68例慢性髓细胞性白血病患者作为研究对象,所有患者均给予伊马替尼治疗,将68例患者随机分为观察组和对照组,每组34例,给予对照组患者常规护理,给予观察组患者护理干预,对比两组患者不良反应发生状况。结果观察组患者不良反应发生率与对照组相比明显较低,差异具有统计学意义(P<0.05)。观察组患者满意度评分明显高于对照组,差异具有统计学意义(P<0.05)。观察组患者认知功能、社会功能、心理功能、躯体功能评分与对照组相比明显较高,差异具有统计学意义(P<0.05)。结论护理干预能有效减少患者不良反应发生率,提高患者满意度和生活质量,可在慢性髓细胞性白血病患者采取伊马替尼治疗的护理中推广运用。
作者 杨艮平
出处 《当代医学》 2017年第3期148-150,共3页 Contemporary Medicine
  • 相关文献

参考文献5

二级参考文献89

  • 1黄河,蔡真,林茂芳,谢万灼,梁彬,李黎,何静松,罗依,郑伟燕,张洁,叶琇锦,胡晓蓉,陈水云,金爱云.非亲缘异基因骨髓移植治疗儿童白血病[J].中华儿科杂志,2004,42(11):835-839. 被引量:7
  • 2贺其图,时风桐,袁祖正.包头市白血病流行病学调查[J].内蒙古医学杂志,1993,13(2):3-5. 被引量:10
  • 3江倩,陈珊珊,江滨,江浩,丘镜滢,刘艳荣,张艳,秦亚溱,陆颖,黄晓军,陆道培.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期100例追踪观察[J].中华血液学杂志,2006,27(11):721-726. 被引量:39
  • 4台杰,刘峰,杨潇然,赵君,孙立靖.针刺配合耳穴贴压治疗化疗性呕吐36例[J].江苏中医药,2007,39(7):49-49. 被引量:8
  • 5Deininger M,O′Brien S G,Guilhot F,et al.InternationalRandomized Study of Interferon Vs STI571(IRIS)8-Yearfollow up:sustained survival and low risk for progression orevents in patients with newly diagnosed chronic myeloidleukemia in chronic phase(CML-CP)treated with imatinib.[J].Blood(ASH Annual Meeting Abstracts),2009,114(11):1126.
  • 6Marin D,Marktel S,Szydlo R,et al.Survival of patients withchronic-phase chronic myeloid leukaemia on imatinib afterfailure on interferon alfa[J].Lancet,2003,362(9384):617-619.
  • 7Quintas-Cardama A,Kantarjian H,Jones D,et al.Delayedachievement of cytogenetic and molecular response is associatedwith increased risk of progression among patients with chronicmyeloid leukemia in early chronic phase receiving high-dose orstandard-dose imatinib therapy[J].Blood,2009,113(25):6315-6321.
  • 8Castagnetti F,Testoni N,Luatti S,et al.Deletions of thederivative chromosome9do not influence the response and theoutcome of chronic myeloid leukemia in early chronic phasetreated with imatinib mesylate:GIMEMA CML working partyanalysis[J].J Clin Oncol,2010,28(16):2748-2754.
  • 9Cortes J,Quintas-Cardama A,Jones D,et al.Immunemodulation of minimal residual disease in early chronic phasechronic myelogenous leukemia:a randomized trial of frontlinehigh-dose imatinib mesylate with or without pegylatedinterferon alpha-2b and granulocyte-macrophage colony-stimulating factor[J].Cancer,2011,117(3):572-580.
  • 10Poerio A,Amabile M,Iacobucci I,et al.Better molecularresponse to imatinib in early chronic phase versus late chronicphase chronic myeloid leukemia patients in completecytogenetic response:a comparison at24months of2clinicaltrials of the GIMEMA working party on CML(GIMEMA-CML).[J].Blood(ASH Annual Meeting Abstracts),2005,106(11):1096.

共引文献105

同被引文献30

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部